Brain Cancer

7 protocols meet the specified criteria.

  • 20324

    ON-TRK: PrOspective Non-Interventional Study in Patients with Locally Advanced or Metastatic TRK Fusion Cancer Treated with Larotrectinib

  • A051901

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (NIVO-MR2) Induction followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

  • A151804

    Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

  • COG-ACNS1833

    A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

  • EAY191

    Molecular Analysis for Combination Therapy Choice (ComboMATCH)

  • F8394-201

    A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations

  • S2013

    Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study